Nifty
:
14677.80
Sensex
:
48732.55
-18.70 (-0.13%)
41.75 (0.09%)
Nifty
Sensex
:
:
14677.80
48732.55
-18.70 (-0.13%)
41.75 (0.09%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 500257 | NSE: LUPIN

NSE BSE
1178.45
14-May-2021
  • Open
  • High
  • Low
  • Previous Close
  •  1210.00
  •  1233.80
  •  1166.00
  •  1212.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  5406128
  •  64367.24
  •  1246.80
  •  828.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 53,485.50
  • 43.97
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 57,336.52
  • 0.51%
  • 3.87

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.86%
  • 0.50%
  • 10.02%
  • FII
  • DII
  • Others
  • 17.87%
  • 22.23%
  • 2.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.21
  • 3.38
  • 2.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.71
  • -7.66
  • -4.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.07
  • -23.79
  • -18.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.03
  • 23.10
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.01
  • 3.48
  • 2.95

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.01
  • 14.64
  • 14.82

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
3,783.10
3,845.74
-1.63%
4,017.36
3,769.27
6.58%
3,835.00
3,882.21
-1.22%
3,527.86
3,877.69
-9.02%
Expenses
3,075.55
3,320.42
-7.37%
3,238.62
3,340.17
-3.04%
3,253.83
3,241.64
0.38%
3,039.78
3,130.86
-2.91%
EBITDA
707.55
525.32
34.69%
778.74
429.10
81.48%
581.17
640.57
-9.27%
488.08
746.83
-34.65%
EBIDTM
18.70%
13.66%
19.38%
11.38%
15.15%
16.50%
13.84%
19.26%
Other Income
58.22
208.60
-72.09%
21.17
93.59
-77.38%
24.96
127.96
-80.49%
43.28
66.59
-35.01%
Interest
31.84
107.38
-70.35%
30.92
88.60
-65.10%
33.62
82.59
-59.29%
44.26
84.41
-47.57%
Depreciation
215.72
214.26
0.68%
244.32
253.23
-3.52%
212.73
252.57
-15.77%
214.64
250.16
-14.20%
PBT
518.21
495.37
4.61%
524.67
-107.82
-
359.78
-113.11
-
272.46
478.85
-43.10%
Tax
54.01
105.07
-48.60%
83.49
767.02
-89.12%
146.70
69.52
111.02%
164.32
215.50
-23.75%
PAT
464.20
390.30
18.93%
441.18
-874.84
-
213.08
-182.63
-
108.14
263.35
-58.94%
PATM
12.27%
10.15%
10.98%
-23.21%
5.56%
-4.70%
3.07%
6.79%
EPS
10.15
8.60
18.02%
9.66
-18.44
-
4.66
-2.81
-
2.36
6.70
-64.78%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
15,163.32
16,836.56
16,751.37
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
Net Sales Growth
-1.38%
0.51%
5.99%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
 
Cost Of Goods Sold
5,362.24
4,962.72
4,436.67
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
Gross Profit
9,801.08
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
GP Margin
64.64%
70.52%
73.51%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
Total Expenditure
12,607.78
14,362.21
14,082.44
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
Power & Fuel Cost
-
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
% Of Sales
-
2.63%
2.64%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
Employee Cost
-
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
% Of Sales
-
17.74%
16.54%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
Manufacturing Exp.
-
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
% Of Sales
-
11.00%
10.34%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
General & Admin Exp.
-
2,798.71
3,302.60
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
% Of Sales
-
16.62%
19.72%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
Selling & Distn. Exp.
-
1,080.45
1,206.60
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
% Of Sales
-
6.42%
7.20%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
Miscellaneous Exp.
-
238.11
192.55
166.20
283.61
204.82
271.21
283.96
184.88
162.80
547.48
% Of Sales
-
1.41%
1.15%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
EBITDA
2,555.54
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
EBITDA Margin
16.85%
14.70%
15.93%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
Other Income
147.63
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
Interest
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
Depreciation
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
PBT
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Tax
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
Tax Rate
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
PAT
1,226.60
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
PAT before Minority Interest
1,215.20
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
Minority Interest
-11.40
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
PAT Margin
8.09%
-1.63%
3.65%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
PAT Growth
403.75%
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
 
EPS
27.04
-6.03
13.48
5.46
56.19
49.72
52.97
40.48
28.97
19.12
19.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
Share Capital
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
Total Reserves
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
Non-Current Liabilities
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
Secured Loans
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
Unsecured Loans
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
Long Term Provisions
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
Current Liabilities
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
Trade Payables
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
Other Current Liabilities
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
Short Term Borrowings
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
Short Term Provisions
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
Total Liabilities
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
Net Block
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
Gross Block
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
Accumulated Depreciation
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
Non Current Assets
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
Capital Work in Progress
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
Non Current Investment
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
Long Term Loans & Adv.
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
Other Non Current Assets
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
Current Assets
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
Current Investments
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
Inventories
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
Sundry Debtors
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
Cash & Bank
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
Other Current Assets
1,717.86
777.47
621.30
533.43
1,241.22
534.98
532.99
572.33
427.17
628.48
Short Term Loans & Adv.
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
Net Current Assets
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
Total Assets
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
PBT
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Adjustment
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
Changes in Working Capital
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
Cash after chg. in Working capital
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
Net Fixed Assets
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
Net Investments
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
Others
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
Cash from Financing Activity
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
Net Cash Inflow / Outflow
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
Opening Cash & Equivalents
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
Closing Cash & Equivalent
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
ROA
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
ROE
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
ROCE
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
Fixed Asset Turnover
2.12
1.93
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
Receivable days
60.97
66.11
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
Inventory Days
41.97
47.94
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
Payable days
65.89
68.49
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
Cash Conversion Cycle
37.04
45.56
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
Total Debt/Equity
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
Interest Cover
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Lupin reports 18% rise in Q4 consolidated net profit
    14th May 2021, 09:36 AM

    The company has reported a standalone net profit of Rs 316.36 crore for the quarter ended March 31, 2021

    Read More
  • Lupin enters into voluntary licensing agreement with Lilly
    10th May 2021, 13:21 PM

    The timely restricted emergency use of Baricitinib will be an important life-saving treatment for patients with moderate to severe symptoms of COVID-19

    Read More
  • Lupin recalls 17,814 bottles of Cefprozil in US market
    26th Apr 2021, 10:00 AM

    According to the USFDA, the company is recalling the affected lot for being ‘Superpotent’

    Read More
  • Lupin incorporates wholly-owned subsidiary in USA
    21st Apr 2021, 08:14 AM

    LOI will be pursuing partners, financial sponsors and perform such other acts as may be necessary

    Read More
  • Lupin’s healthcare business enters into partnership with Uttarakhand Police
    24th Mar 2021, 11:32 AM

    During the Kumbh, LupinLife will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations

    Read More
  • Lupin launches Authorized Generic Version of Alinia
    10th Mar 2021, 14:36 PM

    Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older

    Read More
  • Lupin’s arm enters into partnership with Endoceutics
    9th Mar 2021, 11:28 AM

    The company has entered into partnership to commercialize Intrarosa in Canada

    Read More
  • Lupin launches Penicillamine Tablets USP
    2nd Mar 2021, 15:12 PM

    Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P.

    Read More
  • Lupin gets approval for Droxidopa Capsules from USFDA
    19th Feb 2021, 15:55 PM

    The product will be manufactured at Lupin’s facility in Nagpur, India

    Read More
  • Lupin launches Posaconazole Delayed-Release Tablets
    17th Feb 2021, 11:58 AM

    Posaconazole Delayed-Release Tablets, 100 mg (RLD: Noxafil) had estimated annual sales of $186 million in the U.S.

    Read More
  • Lupin’s arm recalling 46,479 bottles of anti-viral medication Oseltamivir Phosphate in US market
    15th Feb 2021, 10:30 AM

    The company initiated the recall, which the US health regulator has classified as Class III, on January 21 this year

    Read More
  • Lupin’s consumer healthcare business launches ayurvedic energy supplement for men ‘Be One’
    10th Feb 2021, 14:03 PM

    Be One is a 100% Ayurvedic health and wellness supplement specially developed for men to help them stay energized and healthy

    Read More
  • Lupin gets approval for Tavaborole Topical Solution from USFDA
    9th Feb 2021, 15:43 PM

    The product will be manufactured at Lupin's facility in Pithampur, India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.